// App-Quantinova.ai

3063 : Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and nonsmall cell lung cancer (NSCLC): pooled results from KEYNOTE-001, 002, 006, and 010.

Researchers

Presenter

  • Marianne van Vugt

Principal Investigators

  • Rik de Greef

  • Tomoko Freshwater

  • Eric Mangin

  • Frank van Aarle

  • Anna Kondic

Medical Centers

  • Merck & Co., Inc., Kenilworth, NJ

Locations

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Melanoma

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01295827

  • NCT01905657

  • NCT01704287

  • NCT01866319

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved